News

Archive

February 8, 2022

Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results

Archive

February 2, 2022

Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

Archive

February 1, 2022

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022

Archive

January 24, 2022

Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Archive

January 10, 2022

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones

Archive

January 3, 2022

Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

Archive

December 21, 2021

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Archive

November 30, 2021

Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations

Archive

November 22, 2021

Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Archive

November 5, 2021

Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study

Back to top